Edward Kim, MD, Associate Professor of Radiology and Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai presents case #5 from "Outside Your IO Comfort Zone: Learn...
Alda Tam, MD, Professor, The University of Texas M.D. Anderson Cancer Center, University of Texas MD Anderson Cancer Center presents definitions and rationale behind the treatment of olig...
Constantinos Sofocleous, MD, PhD, FSIR, FCIRSE presents on oligometastatic colorectal cancer. Developed in partnership with the Society for Interventional Oncology.
Kevin Kim, MD, Interventional Oncologist, Director of the Smilow, Interventional Oncology Program, Yale Medicine, presents on oligometastatic lung cancer. Developed in partnership with th...
Thomas Atwell, MD, Professor of Radiology, Mayo Clinic, presents on oligometastatic renal cancer. Developed in partnership with the Society for Interventional Oncology.
Jack Jennings, MD, Assistant Professor of Radiology, Division of Diagnostic Radiology, Section of Musculoskeletal Radiology, Washington University School of Medicine, presents on oligomet...
Gao-Jun Teng, MD, PhD, Professor of Radiology, President, Zhongda Hospital, Southeast University, Nanjing, China discusses IO During COVID: A Global Perspective.
Uei Pua, MD, Senior Consultant, Department of Diagnostic Radiology, Tan Tock Seng Hospital (TTSH)/National Healthcare Group, Singapore, discusses IO in Singapore during the Covid-19 pande...
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Siemens Healthineers and University Hospitals Cleveland News
Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
Embolization is a minimally invasive...
